Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    02-April-2001      
Issue 92 Next Update - 14:00 UTC 08:00 EST    03-April-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya




















Back To Vidyya Motexafin Gadolinium Appears To Improve Treatment And Reduce Death Due To Tumor Progression In Patients With Brain Metastases

Motexafin Gadolinium Is The First Of A New Class Of Drugs Called Texaphyrins

A promising new approach to treating the more than 170,000 cancer patients in the U.S. whose cancer spreads from another part of their body to their brain each year may increase tumor response rates and reduce progression of the disease, according to a study published in this week's Journal of Clinical Oncology.

The multi-center Phase Ib/II clinical trial of the investigational agent, motexafin gadolinium (Xcytrin® Injection, Pharmacyclics, Inc.;, administered in combination with standard whole brain radiation therapy, showed the treatment increased local tumor control, as evidenced by a high tumor response rate (i.e., significant tumor shrinkage) and low rate of death due to tumor progression in the brain.

"We are particularly pleased to see the high tumor response rate, which is nearly double what we have observed in the literature with radiation alone," said Minesh Mehta, M.D., associate professor and interim chair, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, one of the study's lead investigators. "Based on these encouraging results, we conducted a large multi-center international Phase III study designed to measure survival and time to neurologic progression in a similar patient population. Enrollment in this 428-patient trial has been completed, and we expect to report results by the end of this year."

Motexafin gadolinium is the first of a new class of drugs called texaphyrins. It selectively accumulates in cancer cells and disrupts cellular metabolism by a unique mechanism of action. By interfering with the flow of energy in cancer cells, motexafin gadolinium makes the tumor more responsive to the effects of radiation and chemotherapy without increasing damage to normal tissue.

Key Study Findings

Sixty-one patients with brain metastases were enrolled in the combined Phase Ib/II trial. For 10 days, daily intravenous injections of motexafin gadolinium were administered, followed by whole brain radiation treatment each day. Thirty-nine patients were enrolled in the Phase Ib portion of the trial intended to determine optimal dosing and tumor localization using magnetic resonance imaging (MRI), and 22 patients were enrolled in the Phase II portion of the trial designed to assess tumor response and side effect profile.

Eighteen Phase II patients were evaluable for tumor response based on follow-up MRI scans. After a two-month follow-up, tumor response, defined as greater than 50 percent reduction in tumor volume, was seen in 13 of 18 patients (72 percent), significantly higher than the 43 percent reported in previous studies of patients treated with standard whole brain radiation therapy alone. Death due to tumor progression in the brain was just 12 percent, compared to a rate of about 50 percent reported in previous studies of patients treated with radiation alone. MRI scanning showed visual enhancement of the brain metastases for 56 days following administration of motexafin gadolinium, demonstrating how the drug localizes selectively and is retained in the tumors.

The treatment was well tolerated. The most common side effects observed were discoloration of the skin, urine and eyes due to the dark green color of the drug. The discoloration developed gradually after repeated drug dosing, and cleared three to four days after the last dose.

"This is the first treatment of its kind that appears to enhance the beneficial effects of radiation therapy in a clinical setting," said Dr. Patrice Carde, Chef de Service, Department of Medicine, Institut Gustave Roussy, Villejuif, France, lead author of the study.

Brain Metastases: An Increasing Clinical Problem

Approximately 170,000 patients are diagnosed with brain metastases each year in the United States. This number is increasing as cancer patients live longer due to new treatment advances made in the last several years. However, there are few treatment options for patients whose cancer has advanced and spread to the brain.

Metastases in the brain are one of the most devastating consequences of cancer, affecting up to 40 percent of all cancer patients. The majority of brain metastases originate in breast and lung cancers. Brain metastases occur when cancer cells from the primary site migrate (often through the blood stream) and travel to the brain, where they remain and grow. Patients with brain metastases may suffer devastating complications from uncontrolled progression of tumor growth in the brain; these complications include headaches, seizures, paralysis, blindness, neurocognitive deterioration and death. The goal of whole brain radiation therapy is to reverse or prevent neurological deterioration and prevent death due to tumor progression in the brain.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.